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'p < 0.05, "p ~ 0.01 (Student's t test L-C vs PI)
fied by the detergent pluronic F-68 and a variety of lipids, significantly re-
duces myocardial reperfusion injury (RI) in animals and humans as shown in
some initial clinical trials. Potential mechanisms for Fluosol include enhanced
O2 delivery to the reperfused tissue and modulation of various neutrophil
(PMNs) functions. Recent studies in dogs and man demonstrate the same
beneficia: effect for treatment of Rl with the detergent component alone,
RheothRx, which is currently undergoing clinical trials. We have shown that
the effect of Fluosol on PM Ns is related to this detergent. However, pro-
longed infusion (48 hrs) of detergent is required to reduce Rl to the same
extent as Fluosol given over only 1 hr. Possible mechanisms for the benefi-
cial effects of Fluosol (02 delivery vs effects on PMNs) were investigated in
a model of regional ischemia utilizing rabbits undergoing 30 mins of circum-
flex occlusion and 48 hrs of reperfusion. Infarct size (area of necrosis, AN)
was determined histologically and expressed as percent of risk region (area
at risk, AR). Animals received Fluosol (30 cc/kg) with or without 02 or saline
over the first 60 mins of reperfusion. AR was similar in all groups. (Mean ±
SEM of AN/AR (%), n ~ 11 for all groups). The treatment with Fluosol with or
without 02 (44 ± 3 and 40 ± 3, respectively) was significantly (p < 0.05) re-
duced compared to control (63 ± 4). Another group received F-I08, a larger
size pluronic detergent found to be 2.5-fold more potent in suppressing PMN
function in vitro compared to F-68, during the first 3 hrs of reperfusion. This
treatment did not alter the infarct size (63 ± 5). RheothRx was found to form
4 nm micelles in solution whereas Fluosol formed particles approximately
100 times larger. Similar sized particles were formed by substituting the per-
fluorocarbons with mineral oil. The in vitro activity of this pluronic/mineral oil
micelle on PMN function was similar to Fluosol. Infusion of these larger oil
micelles was tolerated by rabbits and used in further infarct studies. Con-
clusions; These studies suggest that (1) reduction of RI by Fluosol is not
due to enhanced 02 delivery by the PFCs to reperfused myocardium and (2)
since the Fluosol emulsion markedly reduces the clearance of the detergent
F-68 (tv,: Fluosol ~ 8 hrs vs RheothRx ~ 1.5 hrs). prolonged PMN suppres-
sion rather than potency of suppression is the mechanism whereby Fluosol
ameliorates RI. FluosoJ's clinical efficacy may be enhanced by prolonging its
infusion to ensure an adequate blood level to suppress PMN function be-
yond the time of reperfusion injury. RheothRx's clinical usefulness may be
facilitated by decreasing its renal clearance by delivering larger micelles of
the detergent in order to produce prolonged PMN suppression with a shorter
infusion time.
Predictors of Early Recovery in Left Ventricular
Function After Primary Angioplasty in Acute
Myocardial Infarction
Luiz A. Mattos, Fausto Feres, Luiz F. Tanajura, Ibraim Pinto, Aurea Chaves,
Marinella Centemero, Gilberta Nunes, Amanda Sousa, J. Eduardo Sousa. Dante
Pazzanese Institute of Cardiology, Sao Paulo. Brazil
Clinical and angiographic data were analysed in 244 pts submitted to a suc-
cessful primary PTCA within 24 hrs of acute MI to determine predictors of
early recovery in LV function. All pts had a LV angiogram before PTCA and at
hospital discharge (HD - mean = 10 days). The end points were: analysis of
arterial patency rate at HD and its relation to ejection fraction (EF) recovery
and in pts with sustained arterial patency (SAPj, which ones exhibit a greater
increase in EF. P values < 0.05 were submitted to multivariate analysis (risk
adjustment).
Variable % Pre EF HD EF GAIN P
Arterial Patency 91 43 ± 9 49± 8 +6.1 ±4% 0.001'
Reocclusion 9 45 ± 8 41 ± 10 -3.4 ± 5%
ONLY PTS WITH SAP:
Anterior MI 52 41 ± 7 47 ± 9 +6.3 ± 4% 002
Inferior MI 48 49 ± 9 52 ± 10 +3.1 ± 2%
Ischemia time < 4 hrs 42 44± 8 53 ± 9 +9.4 ± 5% 0.001*
Ischemia time> 4 hrs 58 44± 9 49± 5 +5.1 ± 2%
Multivessel disease 52 42 ± 9 50 ± 7 +8.1 ± 4% 002
Single vessel disease 48 44± 10 48± 9 +3.9 ± 3%
Baseline EF < 40% 43 33 ± 9 42± 8 +9.6± 5% 0.001'
Baseline EF > 40% 57 51 ± 9 54 ± 5 +3.2 ± 1%
• 1I00CA.
Effects of L-Carnitine on Left Ventricular Function
After Acute Myocardial Infarction. Results of the
CEDIM (Carnitina Ecocardiografia Digitale Infarto
Miocardico) Trial
HISTOLOGV
Q CONTROl
0.004 0.04 0.4
LIOOCAINE I"'o'mil
D RABBIT BlOOD • HUMAN BLOOD
1+
3+
w 100
U
~
u 75
VI
wS so
35E 25
w
:t:
U
Results: 3 months 6 months 12 months
L'l.%-EDV L-C 11.1 ± 30.2 12.7 ± 26.8 191 ± 36.2
PI 18.0 ± 33.0' 19.5 ± 30.6' 28.5 ± 402'
L'l.%-ESV L-C 12.6 ± 41.6 15.1 ± 368 289 ± 51.4
PI 22.5 ± 42.8' 256 ± 42.3" 39.9 ± 55.1'
Sabino Iliceto, Vito Marangelli, Giuseppe Santoro. Luca Bani.
Gaetano D'Ambrosio, Domenico Scrutinio, Paolo Bruzzi, Paul G. Hugenholtz,
Paolo Rizzon, CEDIM Investigators. Institute of Cardiology, Bari, Italy
Limitation of left ventricular (LV) dilatation (LV remodeling) after acute my-
ocardial infarction (AMI) has become an essential therapeutic goal since the
entity of LV dilatation after AMI is now recognized to be the most power-
ful prognostic predictor for clinical outcome. L-Carnitine (L-C) is an essential
compound of cardiac metabolism that favours the optimal utilization of en-
ergetic substrates. Experimental studies have demonstrated that L-C admin-
istration during and after myocardial ischemia restores L-C cardiac depletion
following ischemia and exerts a beneficial effect on LV function. To test the
hypothesis, that timely restoration of adequate intracardiac L-C levels after
AMI could limit LV dilatation on a long-term basis in a clinical setting, a mul-
ticenter, randomized, double-blind, placebo controlled trial was undertaken
(CEOIM trial). 472 pts with first, anterior AMI and high quality entry 20 echo
were enrolled (370/472 pts underwent thrombolysis). Pts were randomized
to placebo (PI) or L-C (6 g/day iv for the first 5 days and 9 g/day orally for the
following 12 months). 20 echo was digitally performed on admission, at 3,
6, 12 months after AMI. 2D echo images were transmitted via modem using
a long-distance network to a Core Laboratory where end-diastolic and end-
systolic volumes (EOV, ESV) were assessed. Baseline clinical and echocar-
diographic characteristics were similar in L-C and PI groups. Percent variation
(L'l. %) of EOV and ESV at 3, 6,12 months from baseline was evaluated in both
PI and L-C groups.
Conclusions; (i) The beneficial effect of lido on infarct size was associated
with a significant reduction in the accumulation of PMNs in the reperfused
rabbit myocardium. (ii) This beneficial effect may occur as a direct inhibitory
effect of lido on PMNs. (iii) This effect of lido on infarct size may also OCCur in
man as human cells respond similarly in vitro to equal doses of lidocaine. (iiii)
Lidocaine may confound the interpretation of other interventions to reduce
infarct size in animals and possibly in man.
1923-21
Congestive heart failure developed in 10 pts (4.2%) on PI vs 4 pts (1.7%) on
L-C. Conclusion; Timely administration of L-C after AM I limits LV dilatation in
the first year after AMI and, therefore, represents a new approach to optimize
LV remodeling after AMI.
Conclusions; Pts with SAP' and anterior Ml, multivessel disease, baseline
EF < 40%' and early reperfusion' are likely to benefit most from primary
PTCA in acute myocardial infarction ('independent variables).
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Christopher M. Speidel, Gerrald Galluppi 1, Dana R. Abendschein. Washington
University. St Louis, MO; 1 Monsanto/Searle, St. Louis, MO
Local administration of recombinant tissue factor pathway inhibitor (rTF PI).
the physiologic inhibitor of the tissue factor-factor Vila complex that also in-
hibits factor Xa, attenuates necrosis after reperfusion of ischemic ears in rab-
Fluosol Reduces Myocardial Reperfusion Injury by
Prolonged Suppression of Neutrophils by its
Detergent Component (RheothRx) and not by
Enhancing 02 Delivery
Joao V. Vitola, David A. Ingram, John P. Holsinger, James B. Atkinson, Mervyn
B. Forman, John J. Murray. Vanderbilt University. Nashville. TN
Fluosol, a complex mixture of 02 carrying perfluorocarbons (PFCs) emu lsi-
1923-51 Tissue Factor Pathway Inhibitor Decreases
Myocardial Reperfusion Injury in Dogs
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Although the occluded IRA is a known risk factor for LV remodeling, this
study demonstrates that LV enlargement can occur in patients with patent
IRAs.
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Activity at the Onset of Symptoms and Outcome
of Acute Myocardial Infarction
Ralph A.H. Stewart, Norma J. Restieaux, M. Clare Robertson, Clive J.S. Low,
Gerrard 1. Wilkins. University of Otago, Dunedin, New Zealand
Cardiac Injury in the Critically III: A Surprisingly
Common Finding
Thomas M. Guest. Anand V. Ramanathan, Kenneth B. Schechtman, Jack
H. Ladenson, Allan S. Jaffe. Washington University School of Medicine, St. Louis, MO
Medical intensive care unit(MICU) patients often are subjected to severe car-
diovascular stress and thus may be at risk for myocardial ischemialinfarction.
To determine the incidence of myocardial injury in such patients, we mea-
sured daily levels of cardiac troponin I (cTnl), a long-lived, sensitive and highly
specific plasma marker of cardiac injury. Two hundred twenty-seven consec-
utive patients (242 admissions) were considered for the study; 18 were ex-
cluded due to either suspected infarction on admission or inability to obtain
the required blood samples. The MICU staff evaluated 121 of the 209 pa-
tients (58%) for possible infarction; they were unaware of the cTnl results.
Overall, 32 of the 209 patients (15%) had evidence of myocardial damage
based on a cTnl value :::3.1 ng/ml. Evidence of myocardial injury by cTnl was
present on admission or day 1 in 29 of the 32 patients. Only 37.5% (12/32) of
these patients were diagnosed as having acute infarction by the MICU staff.
An additional 9 patients had elevated values of MBCK but were not thought
to have suffered cardiac damage. Five of these patients met criteria for in-
farction with cTnl while 4 did not. Myocardial injury occurred in 21 patients
without primary cardiac diagnoses. It was present in 6/71 patients with respi-
ratory disease, 5/54 with GI bleeding, 5/16 with sepsis, 2/13 with ketoacido-
sis, 1/5 with electrolyte disturbances, 1/3 with neurologic disease and 1 with
traumatic hemothorax. Mortality for patients with myocardial injury, whether
recognized or not, was 41 % compared to 15% for those without injury (p
< 0.001). Patients with cardiac injury also were more apt to be hypotensive
(75% vs. 50%, P = 0.0071 and require mechanical ventilation (66% vs. 27%,
P < 0.0001). These data indicate that myocardial injury is surprisingly com-
mon in critically ill MICU patients, difficult to recognize, and associated with
increased morbidity and mortality.
Acute Myocardial Infarction: Triggers and
Concomitant Medical Conditions
Monday, March 20, 1995,3:00 p.m.-5:00 p.m.
Ernest N. Morial Convention Center, Hall E
Presentation Hour: 3:00 p.m.-4:00 p.m.
Recent studies have confirmed that vigorous exercise can trigger myocar-
dial infarction (MI), but it is not clear whether outcome is influenced by the
activity at the onset of symptoms. This study compares clinical features and
in hospital mortality for patients (pts) whose symptoms of MI began at rest,
in bed, or during or after exercise.
A standard questionnaire which included information on activity at the on-
set of symptoms, risk factors and outcome was completed following admis-
sion for all pts admitted to the CCU from 1975 to 1993. The study population
is 2468 pts with a first MI. At the onset of symptoms 40% of pts were resting,
33% were in bed and 27% were or had been exercising (>4 METS) during
the preceding 30 minutes (Ex).
Pts with onset during exercise were younger (Ex 59.0 (5010.71, Rest 60.8
(10.4), Bed 61.9 (1 0.6) years, p < 0.001) and more likely to be male (Ex 79%,
Rest 67%, Bed 67%, p < 0.001). Cardiovascular risk factors and time delay
to admission were similar for all groups. After adjusting for age and sex,
pts whose symptoms began during exercise had a lower mortality (OR 0.63,
95% CI 0.44, 0.90) and had fewer in-hospital cardiac arrests (OR 0.61, CI 0.39,
0.95) than those whose symptoms began at rest. Pre-hospital cardiac arrest
was not less likely (OR 1.18, CI 0.82, 1.69). Pts with onset of symptoms in
bed had a higher mortality (OR 1.27, CI 1.00, 1.61) than those with onset at
rest.
Outcome of myocardial infarction is influenced by the activity at the on-
set of symptoms. This may reflect variations in the pathophysiology of MI
occurring under different conditions.
1924-11 6 1
1924-1171
Intravenous Adenosine and Lidocaine to Limit
Reperfusion Injury During Acute Myocardial
Infarction: Preliminary Data
Kirk N. Garratt, Raymond J. Gibbons, Guy S. Reeder, Dennis A. Laudon, Joseph
K. Lobi, David R. Holmes. Jr.. Mayo Clinic, MN
Prior studies suggest that an occluded infarct-related artery (IRA) is a risk fac-
tor for progressive LV remodeling following AMI. The purpose of this study
was to determine whether LV dilatation also occurred in patients with patent
IRAs. Serial echocardiograms at baseline and at 1 year (1 Y) were obtained
in 420 SAVE patients, of whom 185 (44.0%) had a pre-randomization car-
diac catheterization reviewed by a central Core laboratory. A patent IRA was
present in 145 (78.4%) of these patients with both catheterization and echo
data. Catheterization occurred an average of 4.4 ± 4.2 days post AMI. Patent
IRA patients were 55 ± 11 years old, and 76.6% male. Ejection fraction was
31.3% ± 5.8. Echo LV size echo was expressed as end diastolic area (EOA).
and end systolic area (ESA). LV dilatation occurred in the overall group (base-
line EOA 69.1 ± 11.8, 1 Y 73.3 ± 13.1, P < 0.001; baseline ESA 48.6 ± 10.9,
1 Y 53.1 ± 14.2, P < 0.001). Randomization to placebo (PLA, n = 67) or cap-
topril (CAP, n = 78) occurred 3-16 days post AMI. There was a trend for less
LV dilatation in captopril-treated patients.
Adenosine (ADO) and lidocaine (LOO) given priorto restoration of blood flow
reduces reperfusion injury in animals. We conducted a pilot study of intra-
venous ADO and LOO in pts undergoing direct angioplasty for acute my-
ocardial infarction (AMI). Pts with S12 hours of chest pain and electrocar-
diographic evidence of AMI were given LOO 1 mglkg iv bolus and 2 mg/min
iv infusion beginning at the time of recruitment, and ADO 70 mcg/kg iv in-
fusion beginning when coronary occlusion (TIMI grade 0-1 blood flow) was
confirmed angiographically. Pts with bronchospasm, blood pressure <100
mmHg, or > 1° heart block were excluded. ADO and LOO were given for 1
hour after vessel patency was restored. Myocardial area at risk and final in-
farction area were measured with serial Tc-99m-sestamibi perfusion studies
(prior to angioplasty, before hospital discharge and 6 weeks after discharge).
A salvage index (51) was constructed by correcting the change in sestamibi
perfusion defect for the mass of myocardium at risk. Analysis of 25 patients
completing the protocol revealed a mean (±SO) salvage of 20 ± 17% and 51
= 0.55. Salvage and 51 were 25 ± 18% and 0.54 for anterior infarctions, 13 ±
5% and 0.57 for inferior infarctions, respectively. These data were compared
to an historical control group consisting of 50 patients undergoing direct an-
gioplasty for AMI without adjunctive AOO/LOO. After adjustment for time to
treatment and perfusion nadir, analysis of covariance revealed a similar de-
gree of early salvage in the study and control groups (p = 0.3). However, at 6
weeks, the median infarct size for study pts was O. Using logistic regression
analysis, significantly more study pts had no final measureable infarction at
6 weeks than control pts at hospital discharge Ip = 0.007). After adjusting
for infarct size, location and time to treatment, this difference persisted (p =
0.04).
Conclusions; Adjunctive ADO and LOO during angioplasty for AM I may
favorably affect late final infarction size. Randomized studies assessing 6
week final infarction size are needed.
bits. To determine whether rTFPllimits myocardial reperfusion injury, either
rTFPI (1 00 /lglkg/min, n = 7). heparin (bolus: 150 Ulkg; infusion: 50 Ulkglhr, n
= 4) or arginine-phosphate vehicle (n = 7) were administered intravenously
to conscious dogs beginning 15 min before and for 60 min after release
from a 2 hr balloon occlusion of the proximal left anterior descending coro-
nary artery. Reperfusion was maintained as verified with a proximal Doppler
probe. Animals given rTFPI exhibited increases in PT (21 ± 7 (SO) sec, n
= 7, P < 0.01 compared with baseline) but no increase in aPTI, whereas
those given heparin exhibited marked increases in aPTI (72 ± 9 sec, n = 3,
P < 0.01). Two days after reperfusion, the coronary artery was reoccluded,
the heart was perfused with Lissamine green to delineate the area at risk,
and infarcted areas were demarcated by incubation of LV sections in 2,3,5-
triphenyl-tetrazolium chloride (TIC). Risk and infarcted areas were quantified
by computerized planimetry. Risk area was similar among groups (28 ± 7%
of LV in rTFPl, 31 ± 5% in heparin, 30 ± 3% in vehicle), but infarct area ex-
pressed as a percentage of the area at risk decreased significantly in dogs
which received rTFPI (17 ± 16%) compared with either heparin (39 ± 23%, p
= 0.09), or vehicle (39 ± 21 %, P = 0.04). Thus, rTFPI appears to limit myocar-
dial reperfusion injury and may do so either by more efficient anticoagulation
or by a mechanism other than inhibition of prothrombin activation.
Infarct Artery Patency does not Prevent LV
Remodeling
Gervasio Lamas, Martin St. John Sutton, Greg Flaker, Gary Mitchell, Sidney Smith,
Bernard Gersh, Eugene Braunwald, Marc Pfeffer, SAVE Investigators. Mount Sinai
Medical Center and the University of Miami School of Medicine, Miami Beach FL
